<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330056</url>
  </required_header>
  <id_info>
    <org_study_id>2010-001</org_study_id>
    <nct_id>NCT01330056</nct_id>
  </id_info>
  <brief_title>Functional Organ Preservation Surgery</brief_title>
  <acronym>FOPS</acronym>
  <official_title>A Prospective Randomized Controlled Trial of Functional Organ Preservation Surgery vs. Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized controlled trial comparing functional organ preservation&#xD;
      surgery (FOPS) vs. radiotherapy or chemoradiotherapy as the first treatment modality for&#xD;
      patients with head an neck squamous cell carcinoma arising in the oropharynx, larynx and&#xD;
      hypopharynx. This study has a hypothesis that the FOPS is an effective treatment strategy to&#xD;
      preserve the organ function without compromising oncologic safety and survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective study compare the following items between two groups:&#xD;
&#xD;
        -  Functional outcomes: laryngeal, pharyngeal, and quality of life&#xD;
&#xD;
        -  Oncological outcomes: survivals, locoregional controls&#xD;
&#xD;
        -  Combined imaging and molecular biomarkers with follow-up data&#xD;
&#xD;
      The functional organ preservation surgery (FOPS) is defined as a surgery preserving the&#xD;
      laryngeal or pharyngeal function regardless of open or transoral route. The FOPS may include:&#xD;
&#xD;
        -  Radical tonsillectomy or other oropharyngeal resection&#xD;
&#xD;
        -  Partial laryngectomy or pharyngectomy&#xD;
&#xD;
        -  Transoral laser microresection&#xD;
&#xD;
        -  Transoral robotic surgery (TORS)&#xD;
&#xD;
        -  Reconstructive surgery may be combined with primary resection&#xD;
&#xD;
        -  Neck dissection may be indicated in some patients&#xD;
&#xD;
        -  Postoperative radiotherapy or chemoradiotherapy may be indicated in some patients&#xD;
           according to their pathologic reports.&#xD;
&#xD;
      The standard concurrent chemoradiotherapy (CRT) is generally used but radiotherapy (RT) alone&#xD;
      may be indicated for some patients under tumor-board discussion. The salvage surgery may be&#xD;
      indicated for patients with residual or recurrent diseases after CRT or RT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Organ preservation rate</measure>
    <time_frame>2 years</time_frame>
    <description>The larynge and pharyngeal functions are compared between two groups. The time frame may be extended to 5 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>2 years</time_frame>
    <description>The time frame may be extended to 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional control rate</measure>
    <time_frame>2 years</time_frame>
    <description>The time frame may be extended to 5 years</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">264</enrollment>
  <condition>Organ Preservation</condition>
  <arm_group>
    <arm_group_label>FOPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Functional organ preservation surgery (FOPS) group as a first-line treatment modality&#xD;
Postoperative RT or CRT may be included for the patients of this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concurrent chemoradiotherapy or radiotherapy group as a first-line treatment modality&#xD;
Salvage surgery may be applied for the patients for persistent or recurrent cancers after CRT or RT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FOPS</intervention_name>
    <description>Functional organ preservation (FOPS) as a first-line treatment modality&#xD;
Postoperative RT or CRT may be included for the patients of this group.</description>
    <arm_group_label>FOPS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CRT</intervention_name>
    <description>Concurrent chemoradiotherapy as a first-line treatment modality&#xD;
Salvage surgery may be applied for the patients with persistent or recurrent cancers after RT or CRT</description>
    <arm_group_label>CRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with squamous cell carcinomas arising in the oropharynx, larynx, or&#xD;
             hypopharynx&#xD;
&#xD;
          -  Resectable tumors without distant metastases&#xD;
&#xD;
          -  age range: 18-80 years&#xD;
&#xD;
          -  Pretreatment Karnofsky performance scale &gt; or 70%&#xD;
&#xD;
          -  Operable patients&#xD;
&#xD;
          -  No significant loss of pretreatment larynx and pharyngeal functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a present or previous history of other cancers except benign tumors,&#xD;
             premalignant lesions, carcinoma-in-situ (at some organ sites), well-differentiated&#xD;
             thyroid carcinoma and low-grade salivary gland cancers (from tumor-board decision&#xD;
             whether the tumors significantly affect the survival outcomes)&#xD;
&#xD;
          -  Other organ-site cancers&#xD;
&#xD;
          -  Low-performance status or non-operable patients&#xD;
&#xD;
          -  Non-resectable or distant-metastatic tumors&#xD;
&#xD;
          -  Extensive primary or neck nodal diseases&#xD;
&#xD;
          -  Significant pretreament loss of laryngeal or pharyngeal functions&#xD;
&#xD;
          -  cT1N0 glottic carcinomas&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong-Lyel Roh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Jong-Lyel Roh</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Laryngeal and pharyngeal preservation, survivals</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

